1
|
Escure G, Fournier E, Saade C, Issa LHB, Arib I, Tilmont R, Gazeau N, Thiam BM, Chovet M, Delforge M, Gower N, Fléchon L, Cavalieri D, Chauvet P, Nudel M, Goursaud L, Berthon C, Quesnel B, Facon T, Preudhomme C, Duployez N, Manier S. Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes. Haematologica 2024; 109:1289-1292. [PMID: 37855058 PMCID: PMC10985426 DOI: 10.3324/haematol.2023.284050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Accepted: 10/11/2023] [Indexed: 10/20/2023] Open
Abstract
Not available.
Collapse
Affiliation(s)
| | - Elise Fournier
- Department of Biology Pathology, Lille University Hospital, Lille
| | - Cynthia Saade
- Department of Hematology, Lille University Hospital, Lille
| | | | - Inès Arib
- Department of Hematology, Lille University Hospital, Lille
| | - Rémi Tilmont
- Department of Hematology, Lille University Hospital, Lille
| | - Nicolas Gazeau
- Department of Hematology, Lille University Hospital, Lille
| | - Binta M Thiam
- Department of Hematology, Lille University Hospital, Lille
| | - Morgane Chovet
- Department of Hematology, Lille University Hospital, Lille
| | | | - Nicolas Gower
- Department of Hematology, Lille University Hospital, Lille
| | - Léa Fléchon
- Canther Unit, INSERM UMR-S1277, CNRS UMR9020, ONCOLille, Lille University
| | | | - Paul Chauvet
- Department of Hematology, Lille University Hospital, Lille
| | - Morgane Nudel
- Department of Hematology, Lille University Hospital, Lille
| | - Laure Goursaud
- Department of Hematology, Lille University Hospital, Lille
| | - Céline Berthon
- Department of Hematology, Lille University Hospital, Lille
| | - Bruno Quesnel
- Department of Hematology, Lille University Hospital, Lille, France; Canther Unit, INSERM UMR-S1277, CNRS UMR9020, ONCOLille, Lille University
| | - Thierry Facon
- Department of Hematology, Lille University Hospital, Lille
| | - Claude Preudhomme
- Department of Hematology, Lille University Hospital, Lille, France; Canther Unit, INSERM UMR-S1277, CNRS UMR9020, ONCOLille, Lille University
| | - Nicolas Duployez
- Department of Biology Pathology, Lille University Hospital, Lille, France; Canther Unit, INSERM UMR-S1277, CNRS UMR9020, ONCOLille, Lille University
| | - Salomon Manier
- Department of Hematology, Lille University Hospital, Lille, France; Canther Unit, INSERM UMR-S1277, CNRS UMR9020, ONCOLille, Lille University.
| |
Collapse
|
2
|
Jabbour E, Zugmaier G, Agrawal V, Martínez-Sánchez P, Rifón Roca JJ, Cassaday RD, Böll B, Rijneveld A, Abdul-Hay M, Huguet F, Cluzeau T, Díaz MT, Vucinic V, González-Campos J, Rambaldi A, Schwartz S, Berthon C, Hernández-Rivas JM, Gordon PR, Brüggemann M, Hamidi A, Chen Y, Wong HL, Panwar B, Katlinskaya Y, Markovic A, Kantarjian H. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol 2024; 99:586-595. [PMID: 38317420 DOI: 10.1002/ajh.27227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Revised: 01/05/2024] [Accepted: 01/08/2024] [Indexed: 02/07/2024]
Abstract
Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3+ T-cells to engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of administration. In the expansion phase of a multi-institutional phase 1b trial (ClinicalTrials.gov, NCT04521231), heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) received SC blinatumomab at two doses: (1) 250 μg once daily (QD) for week 1 and 500 μg three times weekly (TIW) thereafter (250 μg/500 μg) or (2) 500 μg QD for week 1 and 1000 μg TIW thereafter (500 μg/1000 μg). The primary endpoint was complete remission/complete remission with partial hematologic recovery (CR/CRh) within two cycles. At the data cutoff of September 15, 2023, 29 patients were treated: 14 at the 250 μg/500 μg dose and 13 at 500 μg/1000 μg dose. Data from two ineligible patients were excluded. At the end of two cycles, 12 of 14 patients (85.7%) from the 250 μg/500 μg dose achieved CR/CRh of which nine patients (75.0%) were negative for measurable residual disease (MRD; <10-4 leukemic blasts). At the 500 μg/1000 μg dose, 12 of 13 patients (92.3%) achieved CR/CRh; all 12 patients (100.0%) were MRD-negative. No treatment-related grade 4 cytokine release syndrome (CRS) or neurologic events (NEs) were reported. SC injections were well tolerated and all treatment-related grade 3 CRS and NEs responded to standard-of-care management, interruption, or discontinuation. Treatment with SC blinatumomab resulted in high efficacy, with high MRD-negativity rates and acceptable safety profile in heavily pretreated adults with R/R B-ALL.
Collapse
Affiliation(s)
- Elias Jabbour
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | | | - Vaibhav Agrawal
- Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA
| | - Pilar Martínez-Sánchez
- Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain
| | - José J Rifón Roca
- Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain
| | - Ryan D Cassaday
- Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
| | - Boris Böll
- First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany
| | - Anita Rijneveld
- Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands
| | - Maher Abdul-Hay
- Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA
| | - Françoise Huguet
- Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France
| | | | - Mar Tormo Díaz
- Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain
| | - Vladan Vucinic
- Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany
| | | | - Alessandro Rambaldi
- Department of Oncology-Hematology, University of Milan, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
| | - Stefan Schwartz
- Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - Céline Berthon
- Centre Hospitalier Universitaire de Lille, Lille, France
| | - Jesús María Hernández-Rivas
- IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain
- Department of Hematology, University Hospital of Salamanca, Salamanca, Spain
- CIBERONC, Research Group CB16/12/00233, Salamanca, Spain
| | | | - Monika Brüggemann
- Department of Hematology, University of Schleswig-Holstein, Kiel, Germany
| | - Ali Hamidi
- Amgen Inc., Thousand Oaks, California, USA
| | - Yuqi Chen
- Amgen Inc., Thousand Oaks, California, USA
| | - Hansen L Wong
- Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, California, USA
| | | | | | | | - Hagop Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
3
|
Podvin B, Soenen V, Dumezy F, Herlem J, Berthon C, Guermouche H, Thibaud V, Pascal L, Duployez N, Charpentier A. A new combination of monocytic scores to support diagnosis of chronic myelomonocytic leukemia according to novel classifications. Int J Lab Hematol 2023; 45:791-794. [PMID: 36967295 DOI: 10.1111/ijlh.14067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 03/04/2023] [Indexed: 03/29/2023]
Affiliation(s)
- Benjamin Podvin
- Laboratory of Hematology, CHU Lille, Lille, France
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| | | | | | - Julien Herlem
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| | - Céline Berthon
- CHU Lille, Department of Hematology, Huriez Hospital, Lille, France
| | | | - Vincent Thibaud
- Hematology Department, Hospital Group of Lille Catholic University, Lille, France
| | - Laurent Pascal
- Hematology Department, Hospital Group of Lille Catholic University, Lille, France
| | - Nicolas Duployez
- Laboratory of Hematology, CHU Lille, Lille, France
- Plasticity and Resistance to Therapies, Univ. Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Lille, France
| | - Agnès Charpentier
- Laboratory of Hematology, Hospital Group of Lille Catholic University, Lille, France
| |
Collapse
|
4
|
Garnham A, Bruon F, Berthon C, Lebon D, Parimi M, Polya R, Makhloufi KM, Dramard-Goasdoue MH. French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study. Oncol Ther 2023; 11:375-389. [PMID: 37578642 PMCID: PMC10447689 DOI: 10.1007/s40487-023-00239-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Accepted: 06/30/2023] [Indexed: 08/15/2023] Open
Abstract
INTRODUCTION There is a dearth of evidence to document treatment of FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) in real-world settings before the introduction of FLT3 inhibitors. A retrospective cohort study was conducted to understand treatment practices prior to the availability of FLT3 inhibitors in patients with FLT3-mutated AML from two registries in France. METHODS Patient data from January 1, 2009 to December 31, 2017 were collected from the Hauts-de-France and Midi-Pyrénées registries. Patients aged ≥ 18 years at diagnosis with FLT3-mutated AML were included. Demographic and disease characteristics of patients with FLT3-mutated AML and relapsed or refractory (R/R) FLT3-mutated AML were documented. Treatment regimens, overall survival (OS), and event-free survival were assessed in patients with R/R FLT3-mutated AML who did not participate in clinical trials. RESULTS Overall, 819 and 1244 adult patients with AML from the Midi-Pyrénées and Hauts-de-France cohorts, respectively, underwent FLT3 mutation testing; 172 (21.0%) and 263 (21.1%) patients, respectively, had a FLT3 mutation. Primary R/R status was identified in 41.3% (n = 71/172) of the Midi-Pyrénées and 34.6% (n = 91/263) of the Hauts-de-France cohorts. Before R/R AML diagnosis, 82.0% and 97.5% of patients in the Midi-Pyrénées and Hauts-de-France cohorts, respectively, achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) following induction chemotherapy; after diagnosis of R/R AML, CR/CRi rates with salvage therapy were 33.3% and 28.1%, respectively. Median OS (interquartile range) in patients receiving salvage therapy (n = 49, n = 78) was 5.2 (2.3-11.1) and 6.1 (2.5-35.2) months, in the Midi-Pyrénées and Hauts-de-France cohorts, respectively. Across both cohorts, patients with R/R FLT3-mutated AML had low rates of CR/CRi with salvage therapy and a median OS of approximately 6 months. CONCLUSION Before FLT3 inhibitor availability, real-world treatment patterns and outcomes in French patients with R/R FLT3-mutated AML were consistent with clinical trial data, highlighting a poor prognosis and unmet need for effective treatment.
Collapse
Affiliation(s)
- Andy Garnham
- Astellas Pharma Europe Ltd., Addlestone, Surrey, UK.
- Clear Health Economics Ltd., Gateshaw Shillinglee Road, Plaistow, Billingshurst, Sussex, RH14 0PQ, UK.
| | - Franck Bruon
- Astellas Pharma S.A.S., Levallois-Perret, France
| | - Céline Berthon
- Centre Hospitalier Universitaire de Lille, Lille, France
| | - Delphine Lebon
- Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | | | | | | | | |
Collapse
|
5
|
Vasseur L, Fenwarth L, Lambert J, de Botton S, Figeac M, Villenet C, Heiblig M, Dumas PY, Récher C, Berthon C, Lemasle E, Lebon D, Lambert J, Terré C, Celli-Lebras K, Dombret H, Preudhomme C, Cheok M, Itzykson R, Duployez N. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study. Blood Adv 2023; 7:4024-4034. [PMID: 37205853 PMCID: PMC10410128 DOI: 10.1182/bloodadvances.2023010155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 04/24/2023] [Accepted: 05/09/2023] [Indexed: 05/21/2023] Open
Abstract
Whether the LSC17 gene expression can improve risk stratification in the context of next generation sequencing-based risk stratification and measurable residual disease (MRD) in patients with intensively treated AML has not been explored. We analyzed LSC17 in 504 adult patients prospectively treated in the ALFA-0702 trial. RUNX1 or TP53 mutations were associated with higher LSC1 scores while CEBPA and NPM1 mutations were associated with lower scores. Patients with high LSC17 scores had a lower rate of complete response (CR) in a multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European LeukemiaNet 2022 (ELN22), age, and white blood cell count (WBC). LSC17-high status was associated with shorter overall survival (OS) (3-year OS: 70.0% vs 52.7% in patients with LSC17-low status; P < .0001). In a multivariable analysis considering ELN22, age, and WBC, patients with LSC17-high status had shorter disease-free survival (DFS) (hazard ratio [HR], 1.36; P = .048) than those with LSC17-low status. In 123 patients with NPM1-mutated AML in CR, LSC17-high status predicted poorer DFS (HR, 2.34; P = .01), independent of age, WBC, ELN22 risk, and NPM1-MRD. LSC-low status and negative NPM1-MRD identified a subset comprising 48% of patients with mutated NPM1 with a 3-year OS from CR of 93.1% compared with 60.7% in those with LSC17-high status and/or positive NPM1-MRD (P = .0001). Overall, LSC17 assessment refines genetic risk stratification in adult patients with AML treated intensively. Combined with MRD, LSC17 identifies a subset of patients with NPM1-mutated AML with excellent clinical outcome.
Collapse
Affiliation(s)
- Loïc Vasseur
- Adolescents and Young Adults Hematology Department, St-Louis University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
- Biostatistical Department, St-Louis University Hospital, AP-HP, Paris, France
| | - Laurène Fenwarth
- CNRS, INSERM, CHU Lille, UMR9020-U1277 - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France
- Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| | - Jérôme Lambert
- Biostatistical Department, St-Louis University Hospital, AP-HP, Paris, France
| | - Stéphane de Botton
- Département d’hématologie et Département d’innovation thérapeutique, Gustave Roussy, Villejuif, France
| | - Martin Figeac
- CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, University of Lille, Lille, France
| | - Céline Villenet
- CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, University of Lille, Lille, France
| | - Maël Heiblig
- Hematology Department, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre-Benite, France
| | - Pierre-Yves Dumas
- Department of Clinical Hematology, Bordeaux University Hospital, PESSAC, France
| | - Christian Récher
- Service d'Hématologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | | | - Emilie Lemasle
- Hematology Department, Henri-Becquerel Cancer Center, Rouen, France
| | - Delphine Lebon
- Service d’Hématologie Clinique et Thérapie cellulaire, CHU d’Amiens, Amiens, France
| | - Juliette Lambert
- Service d'Hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France
| | - Christine Terré
- Laboratory of Hematology, Centre Hospitalier de Versailles, Le Chesnay, France
| | | | - Hervé Dombret
- Department of Hematology, St-Louis University Hospital, AP-HP, Paris, France
| | - Claude Preudhomme
- CNRS, INSERM, CHU Lille, UMR9020-U1277 - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France
- Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| | - Meyling Cheok
- CNRS, INSERM, CHU Lille, UMR9020-U1277 - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France
| | - Raphael Itzykson
- Department of Hematology, St-Louis University Hospital, AP-HP, Paris, France
- Génomes, biologie cellulaire et thérapeutique U944, INSERM, CNRS, Université Paris Cité, Paris, France
| | - Nicolas Duployez
- CNRS, INSERM, CHU Lille, UMR9020-U1277 - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France
- Laboratory of Hematology, Centre Hospitalier Universitaire (CHU) Lille, Lille, France
| |
Collapse
|
6
|
Duployez N, Vasseur L, Kim R, Largeaud L, Passet M, L'Haridon A, Lemaire P, Fenwarth L, Geffroy S, Helevaut N, Celli-Lebras K, Adès L, Lebon D, Berthon C, Marceau-Renaut A, Cheok M, Lambert J, Récher C, Raffoux E, Micol JB, Pigneux A, Gardin C, Delabesse E, Soulier J, Hunault M, Dombret H, Itzykson R, Clappier E, Preudhomme C. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia. Leukemia 2023:10.1038/s41375-023-01906-z. [PMID: 37085611 DOI: 10.1038/s41375-023-01906-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 04/06/2023] [Accepted: 04/17/2023] [Indexed: 04/23/2023]
Abstract
Tandem duplications (TDs) of the UBTF gene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-TDs occur in about 3% of patients aged 18-60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF-TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1 mutations (61%), FLT3-ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3-ITD. UBTF-TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF-wild-type patients. In patients enrolled in the ALFA-0702 study (n = 614 patients including 21 with UBTF-TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF-TD patients were 42.9% (95%CI: 23.4-78.5%) and 57.1% (95%CI: 39.5-82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1-mutated clones are frequently selected under ICT. This study supports the recognition of UBTF-TD AML as a new AML entity in adults.
Collapse
Affiliation(s)
- Nicolas Duployez
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France.
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France.
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France.
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France.
| | - Loïc Vasseur
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Rathana Kim
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Laëtitia Largeaud
- Hematology Laboratory, CHU Toulouse, INSERM 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Marie Passet
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Anaïs L'Haridon
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
| | - Pierre Lemaire
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Laurène Fenwarth
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | - Sandrine Geffroy
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | - Nathalie Helevaut
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | | | - Lionel Adès
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Delphine Lebon
- Hematology Department, CHU Amiens-Picardie, Amiens, France
| | - Céline Berthon
- Hematology Department, Claude Huriez Hospital, CHU Lille, Lille, France
| | - Alice Marceau-Renaut
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| | - Meyling Cheok
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Juliette Lambert
- Hematology Department, Versailles Hospital, University Versailles-Saint-Quentin-en-Yvelines, Le Chesnay, France
| | - Christian Récher
- Service d'Hématologie, CHU Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Emmanuel Raffoux
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | | | - Arnaud Pigneux
- Hematology Department, CHU de Bordeaux, Bordeaux, France
| | - Claude Gardin
- Hematology Department, Avicenne Hospital, AP-HP, Bobigny, France
- Unité 3518, Saint-Louis Institute for Research, Université de Paris, Paris, France
| | - Eric Delabesse
- Hematology Laboratory, CHU Toulouse, INSERM 1037, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Jean Soulier
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Mathilde Hunault
- Hematology Department, Université d'Angers, Université de Nantes, CHU Angers, Inserm, CNRS, CRCI2NA, SFR ICAT, F‑49000, Angers, France
- Fédération Hospitalo-Universitaire, Grand-Ouest Acute Leukemia, Angers, France
| | - Hervé Dombret
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
- Unité 3518, Saint-Louis Institute for Research, Université de Paris, Paris, France
| | - Raphael Itzykson
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Emmanuelle Clappier
- Université Paris Cité, Génomes, Biologie Cellulaire et Thérapeutique U944, INSERM, CNRS, F-75010, Paris, France
- Laboratoire de biologie médicale multisites SeqOIA - FMG2025, Paris, France
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Claude Preudhomme
- Université de Lille, Unité 1277-Canther, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
- Hematology Laboratory, Centre Hospitalier Universitaire (CHU) de Lille, Lille, France
| |
Collapse
|
7
|
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. Clin Cancer Res 2022; 28:5211-5220. [PMID: 36201165 DOI: 10.1158/1078-0432.ccr-22-1622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/27/2022] [Accepted: 10/04/2022] [Indexed: 01/24/2023]
Abstract
PURPOSE To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). EXPERIMENTAL DESIGN In a French cancer center, we identified and described the profiles of 13 t-MN diagnosed among 37 patients with ovarian cancer referred to hematology consultation for cytopenia under PARPi. Next, we described these 13 t-MN post-PARPi among 37 t-MN post ovarian cancer according to PARPi exposure. Finally, we described 69 t-MN post-PARPi in a national cohort. RESULTS From 2016 to 2021, cumulative incidence of t-MN was 3.5% (13/373) among patients with ovarian cancer treated with PARPi. At time of hematologic consultation, patients with t-MN had a longer PARPi exposure (9 vs. 3 months, P = 0.01), lower platelet count (74 vs. 173 G/L, P = 0.0005), and more cytopenias (2 vs. 1, P = 0.0005). Compared with t-MN not exposed to PARPi, patients with t-MN-PARPi had more BRCA1/2 germline mutation (61.5% vs. 0%, P = 0.03) but similar overall survival (OS). In the national cohort, most t-MN post-PARPi had a complex karyotype (61%) associated with a high rate of TP53 mutation (71%). Median OS was 9.6 months (interquartile range, 4-14.6). In multivariate analysis, a longer time between end of PARPi and t-MN (HR, 1.046; P = 0.02), olaparib compared with other PARPi (HR, 5.82; P = 0.003) and acute myeloid leukemia (HR, 2.485; P = 0.01) were associated with shorter OS. CONCLUSIONS In a large series, we described a high incidence of t-MN post-PARPi associated with unfavorable cytogenetic and molecular abnormalities leading to poor OS. Early detection is crucial, particularly in cases of delayed cytopenia.
Collapse
Affiliation(s)
- Vincent Marmouset
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Justine Decroocq
- Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Service d'Hématologie Clinique, Hôpital Cochin, Paris, France
| | - Sylvain Garciaz
- Institut Paoli Calmettes, Marseille, France
- Cancer Research Center of Marseille, INSERM U1068, Aix-Marseille University, Marseille, France
| | | | - Amine Belhabri
- Department of Oncology, Centre Leon Berard, Lyon, France
| | - Sarah Bertoli
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | | | - Célestine Simand
- Department of Hematology, Institute for Cancer Strasbourg-Europe (ICANS), Strasbourg University, Strasbourg, France
| | - Sylvain Chantepie
- Department of Clinical Hematology, Caen University Hospital, Caen, France
| | - Madalina Uzunov
- Service d'hématologie adulte, Hôpital Pitié-Salpêtrière, Paris, France
| | - Alexis Genthon
- Department of Clinical Hematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR-S 938, Paris, France
| | - Céline Berthon
- Department of Hematology, CHU Lille, Lille, France
- University of Lille, CNRS, Inserm, CHU Lille, IRCL, UMR9020 - UMR1277 - Canther - Cancer heterogeneity, plasticity and resistance to therapies, Lille, France
| | | | - Pierre-Yves Dumas
- CHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France
| | | | | | - Emilie Lemasle
- Département d'hématologie, Hôpital Henri Becquerel, Rouen, France
| | - Emmanuelle Tavernier
- Hématologie, Institut de Cancérologie-Hématologie Universitaire de Saint Etienne, France
| | - Jérémy Delage
- Département d'hématologie clinique, Saint Eloi, Montpellier, France
| | - Marion Loirat
- Service d'hématologie, Hôpital Saint Nazaire, Saint-Nazaire, France
| | | | - Félix Blanc-Durand
- Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U981, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Patricia Pautier
- Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U981, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Véronique Vergé
- Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Nathalie Auger
- Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | | | | | - Marion Lepelley
- Centre Régional de Pharmacovigilance - Addictovigilance, CHU de Grenoble-Alpes, France
| | - Thomas Boyer
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire d'Amiens, Amiens, France
| | | | | | | | - Matthieu Duchmann
- Université de Paris, Génomes, Biologie Cellulaire et Thérapeutique Unité (U)944, INSERM, Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Pierre-Marie Morice
- Department of Clinical Hematology, Caen University Hospital, Caen, France
- UNICAEN, INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie University, Caen, France
| | | | - Lionel Adès
- Hématologie Sénior Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité, Paris, France
| | - Pierre Fenaux
- Hématologie Sénior Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité, Paris, France
| | - Christian Récher
- Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Hervé Dombret
- Adult Hematology Department, Saint-Louis Hospital, APHP, URP3518, Institut de Recherche Saint-Louis, Université de Paris, Paris, France
| | - Arnaud Pagès
- Bureau de Biostatistique et d'Épidémiologie - Gustave Roussy Équipe Oncostat - CESP U1018 - Inserm, France
| | - Christophe Marzac
- Department of Biology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Alexandra Leary
- Department of Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U981, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Jean-Baptiste Micol
- Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- Interception Program, Personalized Cancer Prevention Center, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- INSERM U1287, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| |
Collapse
|
8
|
Duchmann M, Joudinaud R, Boudry A, Pasanisi J, Di Feo G, Kim R, Bucci M, Chauvel C, Chat L, Larcher L, Pacchiardi K, Mathis S, Raffoux E, Adès L, Berthon C, Clappier E, Roumier C, Puissant A, Preudhomme C, Duployez N, Itzykson R. Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML. Blood Cancer J 2022; 12:136. [PMID: 36151081 PMCID: PMC9508105 DOI: 10.1038/s41408-022-00734-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 09/05/2022] [Accepted: 09/07/2022] [Indexed: 12/02/2022] Open
Affiliation(s)
- Matthieu Duchmann
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Romane Joudinaud
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.,Hematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Augustin Boudry
- Hematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Justine Pasanisi
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Giuseppe Di Feo
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Rathana Kim
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.,Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Maxime Bucci
- Hematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Clémentine Chauvel
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Laureen Chat
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Lise Larcher
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Kim Pacchiardi
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Stéphanie Mathis
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Emmanuel Raffoux
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Lionel Adès
- Hematology Department, Saint Louis Hospital, AP-HP, Paris, France
| | - Céline Berthon
- Hematology Department, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille, France
| | - Emmanuelle Clappier
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France.,Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Christophe Roumier
- Hematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Alexandre Puissant
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France
| | - Claude Preudhomme
- Hematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Nicolas Duployez
- Hematology Laboratory, Unité 1277-Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Institut National de la Santé et de la Recherche Médicale (INSERM), Lille, France
| | - Raphaël Itzykson
- Université Paris Cité, Unité 944/7212-GenCellDi, INSERM and Centre National de la Recherche Scientifique (CNRS), Paris, France. .,Hematology Department, Saint Louis Hospital, AP-HP, Paris, France.
| |
Collapse
|
9
|
Podvin B, Guermouche H, Fournier E, Berthon C, Duployez N, Roche-Lestienne C. Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region. Br J Haematol 2022; 198:413. [PMID: 35603637 DOI: 10.1111/bjh.18223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 04/15/2022] [Accepted: 04/20/2022] [Indexed: 11/27/2022]
Affiliation(s)
| | | | - Elise Fournier
- Laboratory of Haematology, Centre de Biologie Pathologie
| | | | - Nicolas Duployez
- Laboratory of Haematology, Centre de Biologie Pathologie.,Université de Lille, CHU, Lille, France
| | | |
Collapse
|
10
|
Lewuillon C, Guillemette A, Titah S, Shaik FA, Jouy N, Labiad O, Farfariello V, Laguillaumie MO, Idziorek T, Barthélémy A, Peyrouze P, Berthon C, Tarhan MC, Cheok M, Quesnel B, Lemonnier L, Touil Y. Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure. Int J Mol Sci 2022; 23:ijms23105555. [PMID: 35628366 PMCID: PMC9141756 DOI: 10.3390/ijms23105555] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 05/11/2022] [Accepted: 05/13/2022] [Indexed: 12/19/2022] Open
Abstract
Acute myeloid leukemia (AML) is a hematological malignancy with a high risk of relapse. This issue is associated with the development of mechanisms leading to drug resistance that are not yet fully understood. In this context, we previously showed the clinical significance of the ATP binding cassette subfamily B-member 1 (ABCB1) in AML patients, namely its association with stemness markers and an overall worth prognosis. Calcium signaling dysregulations affect numerous cellular functions and are associated with the development of the hallmarks of cancer. However, in AML, calcium-dependent signaling pathways remain poorly investigated. With this study, we show the involvement of the ORAI1 calcium channel in store-operated calcium entry (SOCE), the main calcium entry pathway in non-excitable cells, in two representative human AML cell lines (KG1 and U937) and in primary cells isolated from patients. Moreover, our data suggest that in these models, SOCE varies according to the differentiation status, ABCB1 activity level and leukemic stem cell (LSC) proportion. Finally, we present evidence that ORAI1 expression and SOCE amplitude are modulated during the establishment of an apoptosis resistance phenotype elicited by the chemotherapeutic drug Ara-C. Our results therefore suggest ORAI1/SOCE as potential markers of AML progression and drug resistance apparition.
Collapse
Affiliation(s)
- Clara Lewuillon
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Aurélie Guillemette
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Sofia Titah
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Faruk Azam Shaik
- Institut de Recherche sur le Cancer de Lille (IRCL), F-59000 Lille, France;
- LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo 153-8505, Japan;
| | - Nathalie Jouy
- UMS 2014/US41 Plateformes Lilloises En Biologie Et Sante, Université de Lille, F-59000 Lille, France;
| | - Ossama Labiad
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Valerio Farfariello
- Inserm, U1003-PHYCEL-Physiologie Cellulaire, Université de Lille, F-59000 Lille, France;
- Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, F-59655 Villeneuve d’Ascq, France
| | - Marie-Océane Laguillaumie
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Thierry Idziorek
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Adeline Barthélémy
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Pauline Peyrouze
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Céline Berthon
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Mehmet Cagatay Tarhan
- LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo 153-8505, Japan;
- CNRS, Centrale Lille, Junia, Université Polytechnique Hauts-de-France, UMR 8520—IEMN—Institut d’Electronique de Microélectronique et de Nanotechnologie, Université de Lille, F-59000 Lille, France
| | - Meyling Cheok
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Bruno Quesnel
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
| | - Loïc Lemonnier
- Inserm, U1003-PHYCEL-Physiologie Cellulaire, Université de Lille, F-59000 Lille, France;
- Laboratory of Excellence, Ion Channels Science and Therapeutics, Université de Lille, F-59655 Villeneuve d’Ascq, France
- Correspondence: loï (L.L.); (Y.T.)
| | - Yasmine Touil
- CNRS, Inserm, CHU Lille, UMR 9020, UMR-S 1277—Canther—Cancer Heterogeneity, Plasticity and Resistance to Therapies, Université de Lille, F-59000 Lille, France; (C.L.); (A.G.); (S.T.); (O.L.); (M.-O.L.); (T.I.); (A.B.); (P.P.); (C.B.); (M.C.); (B.Q.)
- Correspondence: loï (L.L.); (Y.T.)
| |
Collapse
|
11
|
Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood 2021; 138:507-519. [PMID: 34410352 DOI: 10.1182/blood.2021011103] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Accepted: 05/05/2021] [Indexed: 02/06/2023] Open
Abstract
To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute Leukemia French Association) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patients with good (n = 13), intermediate (n = 339), or unmeasured (n = 35) cytogenetic risk. TP53 (hazards ratio [HR], 2.49; P = .0003) and KRAS (HR, 3.60; P = .001) mutations independently worsened the OS of patients with poor-risk cytogenetics. In those without poor-risk cytogenetics, NPM1 (HR, 0.57; P = .0004), FLT3 internal tandem duplications with low (HR, 1.85; P = .0005) or high (HR, 3.51; P < 10-4) allelic ratio, DNMT3A (HR, 1.86; P < 10-4), NRAS (HR, 1.54; P = .019), and ASXL1 (HR, 1.89; P = .0003) mutations independently predicted OS. Combining cytogenetic risk and mutations in these 7 genes, 39.1% of patients could be assigned to a "go-go" tier with a 2-year OS of 66.1%, 7.6% to the "no-go" group (2-year OS 2.8%), and 3.3% of to the "slow-go" group (2-year OS of 39.1%; P < 10-5). Across 3 independent validation cohorts, 31.2% to 37.7% and 11.2% to 13.5% of patients were assigned to the go-go and the no-go tiers, respectively, with significant differences in OS between tiers in all 3 trial cohorts (HDF [Hauts-de-France], n = 141, P = .003; and SAL [Study Alliance Leukemia], n = 46; AMLSG [AML Study Group], n = 223, both P < 10-5). The ALFA decision tool is a simple, robust, and discriminant prognostic model for AML patients ≥60 years of age treated with intensive chemotherapy. This model can instruct the design of trials comparing the 7 + 3 standard of care with less intensive regimens.
Collapse
Affiliation(s)
- Raphael Itzykson
- Service Hématologie Adultes, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Génomes, Biologie Cellulaire et Thérapeutique, Unité 944, Université de Paris, Centre National de la Recherche Scientifique (CNRS), INSERM, Paris, France
| | - Elise Fournier
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| | - Céline Berthon
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| | - Christoph Röllig
- Medizinische Klinik and
- Poliklinik 1, Universitätsklinikum Techniche Universität Dresden, Dresden, Germany
| | - Thorsten Braun
- Service d'Hématologie Clinique, Hôpital Avicenne, AP-HP, Bobigny, France
| | - Alice Marceau-Renaut
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| | - Cécile Pautas
- Service d'Hématologie Clinique, Hôpital Henri Mondor, AP-HP, Créteil, France
| | - Olivier Nibourel
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| | - Emilie Lemasle
- Service d'Hématologie, Centre Henri Becquerel, Rouen, France
| | - Jean-Baptiste Micol
- Département d'Hématologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Lionel Adès
- Service Hématologie Seniors, Hôpital Saint-Louis, AP-HP, Paris, France
| | | | - Jean-Valère Malfuson
- Service d'Hématologie Clinique, Hôpital d'Instruction des Armées Percy, Clamart, France
| | - Lauris Gastaud
- Département d'Oncologie Médicale, Centre Antoine Lacassagne, Nice, France
| | - Laure Goursaud
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| | - Emmanuel Raffoux
- Service Hématologie Adultes, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | | | - Philippe Rousselot
- Département d'Hématologie Clinique, Hôpital André Mignot, Centre Hospitalier de Versailles, Le Chesnay, France
- Unité Mixte de Recherche (UMR) 1184, Infectious Disease Models for Innovative Therapies (IDMIT) Department, Université Paris-Saclay, Commissariat à l'Énergie Atomique et Aux Énergies Alternatives (CEA), INSERM, Paris, France
| | - Xavier Thomas
- Service d'Hématologie Clinique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France
| | | | - Thomas Cluzeau
- Service d'Hématologie, Université Cote d'Azur, CHU de Nice, Nice, France
| | - Hubert Serve
- Department of Medicine 2, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany
| | - Nicolas Boissel
- Service Hématologie Adolescents Jeunes Adultes, Hôpital Saint-Louis, AP-HP, Paris, France
| | - Christine Terré
- Laboratoire de Cytogénétique, CH Versailles, Le Chesnay, France
| | | | - Claude Preudhomme
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| | | | - Hervé Dombret
- Service Hématologie Adultes, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Institut de Recherche Saint-Louis (IRSL), Equipe d'Accueil (EA) 3518, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Claude Gardin
- Service d'Hématologie Clinique, Hôpital Avicenne, AP-HP, Bobigny, France
- Institut de Recherche Saint-Louis (IRSL), Equipe d'Accueil (EA) 3518, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Nicolas Duployez
- Département d'Hématologie, Canther (Cancer Heterogeneity, Plasticity and Resistance to Therapies), Unité 1277, Centre Hospitalier Universitaire de Lille, Université de Lille, INSERM, Lille, France
| |
Collapse
|
12
|
Lesieur A, Thomas X, Nibourel O, Boissel N, Fenwarth L, De Botton S, Fournier E, Celli-Lebras K, Raffoux E, Recher C, Lambert J, Berthon C, Pigneux A, Itzykson R, Turlure P, Pautas C, Vargaftig J, Preudhomme C, Dombret H, Duployez N. Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. Haematologica 2021; 106:1767-1769. [PMID: 33299234 PMCID: PMC8168487 DOI: 10.3324/haematol.2020.260133] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Indexed: 12/19/2022] Open
Abstract
Not available.
Collapse
Affiliation(s)
| | - Xavier Thomas
- Hospices Civils de Lyon, Lyon-Sud University Hospital, Department of Hematology, Lyon
| | - Olivier Nibourel
- CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille
| | - Nicolas Boissel
- AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris
| | - Laurène Fenwarth
- CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille
| | | | - Elise Fournier
- CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille
| | - Karine Celli-Lebras
- AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris
| | - Emmanuel Raffoux
- AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris
| | - Christian Recher
- Toulouse Cancer University Institute, Department of Hematology, Toulouse
| | | | - Céline Berthon
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, FRANCE; CHU Lille, Department of Clinic Hematology, F-59000 Lille
| | - Arnaud Pigneux
- Bordeaux Haut-Lévêque University Hospital, Department of Hematology, Pessac
| | - Raphael Itzykson
- AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris
| | - Pascal Turlure
- CHU Limoges, Univ. Limoges, Department of Hematology, Limoges
| | - Cécile Pautas
- AP-HP, Department of Hematology, Henri Mondor Hospital, Créteil
| | | | - Claude Preudhomme
- CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille
| | - Hervé Dombret
- AP-HP, Saint-Louis Hospital, Department of Hematology, Saint-Louis Research Institute, Université de Paris, Paris
| | - Nicolas Duployez
- CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE; Univ. Lille, CNRS, Inserm, CHU Lille, Institut de Recherche contre le Cancer de Lille, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille.
| |
Collapse
|
13
|
Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol 2021; 39:1575-1583. [PMID: 33600210 PMCID: PMC8099409 DOI: 10.1200/jco.20.02342] [Citation(s) in RCA: 141] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA) alone, short response duration, and a median overall survival (OS) of approximately 6 months. Eprenetapopt (APR-246), a novel first-in-class drug, leads to p53 protein reconformation and reactivates its proapoptotic and cell-cycle arrest functions.
Collapse
Affiliation(s)
- Thomas Cluzeau
- Cote d'Azur University, Hematology Department, Centre Hospitalier Universitaire of Nice, Nice, France.,Cote d'Azur University, Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France.,GFM
| | - Marie Sebert
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | - Ramy Rahmé
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | | | | | | | | | | | | | | | - Elsa Miekoutima
- Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | | | | | | | - Lise Willems
- GFM.,Hematology Department, Hospital Cochin, APHP, Paris, France
| | - Emmanuel Raffoux
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | | | - Bruno Quesnel
- GFM.,Hematology Department, CHU of Lille, Lille, France
| | - Michael Loschi
- Cote d'Azur University, Hematology Department, Centre Hospitalier Universitaire of Nice, Nice, France.,Cote d'Azur University, Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France
| | | | - David A Sallman
- Hematology Unit, Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Rami Komrokji
- Hematology Unit, Moffitt Cancer Center and Research Institute, Tampa, FL
| | | | - Sylvie Chevret
- SBIM, Hospital Saint Louis, APHP, and Paris University, Paris, France
| | - Lionel Ades
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| | - Pierre Fenaux
- GFM.,Hematology Department, Hospital Saint Louis, Assistance Publique des Hopitaux de Paris (APHP), and Paris University, Paris, France
| |
Collapse
|
14
|
Couturier MA, Thomas X, Raffoux E, Huguet F, Berthon C, Simand C, Gallego-Hernanz MP, Hicheri Y, Hunault Berger M, Saillard C, Leguay T, Loiseau C, Béné MC, Chevallier P. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma 2020; 62:620-629. [DOI: 10.1080/10428194.2020.1844198] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
| | - Xavier Thomas
- Department of Hematology, Hôpital Lyon-Sud, Lyon, France
| | | | - Françoise Huguet
- Department of Hematology, CHRU – Institut Universitaire de Cancer Toulouse – Oncopole, Toulouse, France
| | - Céline Berthon
- Department of Hematology, Hôpital Claude Huriez, CHRU Lille, Lille cedex, France
| | - Célestine Simand
- Department of Hematology, CHU de Hautepierre, Strasbourg, France
| | | | - Yosr Hicheri
- Department of Hematology, Hôpital Saint Eloi, CHRU Montpellier, Montpellier, France
| | | | - Colombe Saillard
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - Thibaut Leguay
- Department of Hematology, Hôpital Haut-Leveque, CHU Bordeaux, Bordeaux, France
| | - Clémence Loiseau
- Department of Hematology Oncology, CH de Versailles, Hôpital André Mignot, Le Chesnay, France
| | | | | |
Collapse
|
15
|
Gazeau N, Derrieux C, Nibourel O, Berthon C, Grardel N, Goursaud L, Boyer T, Dumezy F, Coiteux V, Quesnel B, Preudhomme C, Roche-Lestienne C, Duployez N. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia. Leukemia 2020; 34:2230-2233. [PMID: 31988437 DOI: 10.1038/s41375-020-0715-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Revised: 01/08/2020] [Accepted: 01/14/2020] [Indexed: 11/09/2022]
Affiliation(s)
- Nicolas Gazeau
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
| | | | - Olivier Nibourel
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Céline Berthon
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | | | - Laure Goursaud
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
| | - Thomas Boyer
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Florent Dumezy
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
| | - Valérie Coiteux
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
| | - Bruno Quesnel
- CHU Lille, Hematology Department, Claude Huriez Hospital, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Claude Preudhomme
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
| | - Catherine Roche-Lestienne
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France
- CHU Lille, Institute of Medical Genetics, Jeanne de Flandre Hospital, F-59000, Lille, France
| | - Nicolas Duployez
- CHU Lille, Laboratory of Hematology, F-59000, Lille, France.
- University of Lille, INSERM, UMR-S 1172, F-59000, Lille, France.
| |
Collapse
|
16
|
Berthon C, Rousseau E, Chiambaretta F. [Treatment of submacular hematoma by vitrectomy, subretinal injection of rtPA and gaseous tamponade: A single-center retrospective observational study]. J Fr Ophtalmol 2020; 43:417-426. [PMID: 32192752 DOI: 10.1016/j.jfo.2019.09.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2019] [Revised: 09/20/2019] [Accepted: 09/24/2019] [Indexed: 10/24/2022]
Abstract
OBJECTIVES To evaluate the functional and anatomic recovery of submacular hemorrhage (SMH), treated with vitrectomy, subretinal injection of rtPA and gas tamponade, to highlight the risk factors for their occurrence as well as the factors influencing prognosis. MATERIALS AND METHODS This is a single-center retrospective study. Thirty-two eyes of 30 patients from the Clermont-Ferrand University Hospital were included, with a submacular hemorrhage (SMH) requiring surgical evacuation. The primary endpoint was final postoperative visual recovery. Visual acuities (AV) were converted to the logarithmic minimum angle of resolution scale (logMAR) for statistical analysis. RESULTS The average time from onset of symptoms to surgery was 4.8±3.3 days. The initial VA was 2.1±0.3 logMAR, with an average improvement of 0.7±0.7 logMAR (P=0.0004) at the final visit. The mean thickness of the SMH decreased by 729±352μm (P<0.0001) at the final visit. CONCLUSION Treatment of SMH with vitrectomy, subretinal injection of rtPA and gas tamponade results in a statistically significant improvement in final VA, as well as a significant decrease in SMH thickness on OCT.
Collapse
Affiliation(s)
- C Berthon
- CHU de Gabriel Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
| | - E Rousseau
- CHU de Gabriel Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - F Chiambaretta
- CHU de Gabriel Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| |
Collapse
|
17
|
Fournier E, Debord C, Soenen V, Trillot N, Gonzales F, Tintiller V, Terriou L, Derrieux C, Abou Chahla W, Paris C, Berthon C, Boyer T, Lambilliotte A, Boisseau P, Wuillème S, Fouassier M, Susen S, Preudhomme C, Duployez N. Baseline dysmegakaryopoiesis in inherited thrombocytopenia/platelet disorder with predisposition to haematological malignancies. Br J Haematol 2020; 189:e119-e122. [DOI: 10.1111/bjh.16543] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Elise Fournier
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
| | | | - Valérie Soenen
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
| | - Nathalie Trillot
- Department of Haemostasis and Transfusion CHU Lille Lille France
| | - Fanny Gonzales
- Department of Paediatric Haematology CHU Lille Lille France
| | | | - Louis Terriou
- Department of Internal Medicine and Clinical Immunology CHU Lille Lille France
| | - Coralie Derrieux
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
| | | | - Camille Paris
- Department of Haemostasis and Transfusion CHU Lille Lille France
| | - Céline Berthon
- Department of Clinical Haematology CHU Lille LilleFrance
- CNRS INSERM UMR 9020 – UMR‐S 1277 University of Lille LilleFrance
| | - Thomas Boyer
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
- Laboratory of Haematology CHU Amiens‐Picardie AmiensFrance
| | | | | | | | - Marc Fouassier
- Laboratory of Haematology CHU Nantes Nantes France
- Haemophilia Center CHU Nantes NantesFrance
| | - Sophie Susen
- Department of Haemostasis and Transfusion CHU Lille Lille France
- INSERM UMR 1011 Institut Pasteur de Lille University of Lille Lille France
| | - Claude Preudhomme
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
- CNRS INSERM UMR 9020 – UMR‐S 1277 University of Lille LilleFrance
| | - Nicolas Duployez
- Laboratory of Haematology Centre Hospitalier Universitaire (CHU) Lille Lille France
- CNRS INSERM UMR 9020 – UMR‐S 1277 University of Lille LilleFrance
| |
Collapse
|
18
|
Duployez N, Goursaud L, Fenwarth L, Bories C, Marceau-Renaut A, Boyer T, Fournier E, Nibourel O, Roche-Lestienne C, Huet G, Beauvais D, Berthon C, Cambier N, Quesnel B, Preudhomme C. Familial myeloid malignancies with germline TET2 mutation. Leukemia 2019; 34:1450-1453. [DOI: 10.1038/s41375-019-0675-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 11/07/2019] [Accepted: 11/29/2019] [Indexed: 11/09/2022]
|
19
|
Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton SD, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M. Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study. Cancers (Basel) 2019; 11:cancers11091323. [PMID: 31500210 PMCID: PMC6770064 DOI: 10.3390/cancers11091323] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Revised: 08/23/2019] [Accepted: 09/03/2019] [Indexed: 11/16/2022] Open
Abstract
ABCB1 is a member of the ATP binding cassette transporter family and high ABCB1 activity is considered as a poor prognostic factor in acute myeloid leukemia (AML) treated with intensive chemotherapy, its direct relation with drug resistance remains unclear. We evaluated ABCB1 activity in relation with clinical parameters and treatment response to standard chemotherapy in 321 patients with de novo AML. We assessed multiple clinical relationships of ABCB1 activity—ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated. ABCB1 activity was observed in 58% of AML and was linked to low white blood cell count, high expression of CD34, absence of FLT3-ITD, and absence of mutant NPM1. Moreover, ABCB1 activity was associated with worse overall- and event-free survival. However, ABCB1 activity did not directly lead to ex vivo drug resistance to anthracyclines. We found that ABCB1 was highly correlated with gene expressions of BAALC, CD34, CD200, and CD7, indicating that ABCB1 expression maybe a passenger characteristic of high-risk AML. Furthermore, ABCB1 was inversely correlated to HOX cluster genes and CD33. Thus, low ABCB1 AML patients benefited specifically from anti-CD33 treatment by gemtuzumab ozogamicin in addition to standard chemotherapy. We showed prognostic importance of ABCB1 gene expression, protein expression, and activity. Furthermore, ABCB1 was not directly linked to drug resistance, ABCB1 inhibition did not improve outcome of high ABCB1 AML patients and thus high ABCB1 may represent a passenger characteristic of high-risk AML.
Collapse
Affiliation(s)
- Thomas Boyer
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Fanny Gonzales
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Adeline Barthélémy
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Alice Marceau-Renaut
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Pauline Peyrouze
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Soizic Guihard
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Pascale Lepelley
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Adriana Plesa
- Laboratory of Hematology, Hospital of Lyon-South, 69495 Pierre - Benite, France
| | - Olivier Nibourel
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Carole Delattre
- Laboratory of Hematology, Hospital of Dunkerque, 59240 Dunkerque, France
| | - Marc Wetterwald
- Department of Hematological Diseases, Hospital of Dunkerque, 59240 Dunkerque, France
| | - Nicolas Pottier
- Department of Biochemistry, University Hospital Lille, 59000 Lille, France
| | - Isabelle Plantier
- Department of Hematological Diseases, Hospital of Roubaix, 59100 Roubaix, France
| | - Stéphane de Botton
- Department of Clinical Hematology, Gustave Roussy Institute, 94800 Paris, France
| | - Hervé Dombret
- Department of Hematology, University Paris 7, 75013 Paris, France
| | - Céline Berthon
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
- Department of Hematological Diseases, University Hospital of Lille, 59000 Lille, France
| | - Claude Preudhomme
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Christophe Roumier
- Laboratory of Hematology, CHU Lille, 59000 Lille, France
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France
| | - Meyling Cheok
- Laboratory of Hematology, CHU Lille, 59000 Lille, France.
- Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Jean-Pierre AUBERT Research Centre, 59000 Lille, France.
| |
Collapse
|
20
|
Berthon C, Joubert R, Chiambaretta F. [Phototoxicity by green light laser pointer: Case of a spontaneously resolving macular lesion]. J Fr Ophtalmol 2019; 42:e325-e328. [PMID: 31088743 DOI: 10.1016/j.jfo.2018.12.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Accepted: 12/07/2018] [Indexed: 11/16/2022]
Affiliation(s)
- C Berthon
- CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
| | - R Joubert
- CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| | - F Chiambaretta
- CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France
| |
Collapse
|
21
|
Van de Wyngaert Z, Berthon C, Debarri H, Bories C, Bonnet S, Nudel M, Carpentier B, Legrand C, Barbieux S, Chauvet P, Simonnet A, Willaume A, Bossard JB, Renaud L, Wattebled KJ, Escure G, Branche N, Arib I, Titecat M, Quesnel B, Alfandari S. Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort. Int J Antimicrob Agents 2019; 53:781-788. [PMID: 30831232 DOI: 10.1016/j.ijantimicag.2019.02.020] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 02/14/2019] [Accepted: 02/26/2019] [Indexed: 12/11/2022]
Abstract
OBJECTIVES Antibiotics for febrile neutropenia (FN) in acute myeloid leukaemia (AML) patients undergoing intensive chemotherapy are usually maintained until neutropenia resolution, because of the risk of uncontrolled sepsis in this vulnerable population. This leads to unnecessarily prolonged antimicrobial therapy. METHODS Based on ECIL-4 recommendations, we modified our management strategy and discontinued antibiotics after a pre-established duration in patients treated for a first episode of FN between August 2014 and October 2017. RESULTS Antibiotics were stopped during 62 FN episodes, and maintained in the control group (n = 13). Median age of patients was 54 years. A total of 39 (63%) patients received induction and 23 (37%) consolidation chemotherapy; 36 (58%) patients had fever of unknown origin. Median neutropenia length was 26 days (IQR 24-30). Antibiotics were started at day 9 (IQR 5-13). Most patients received piperacillin-tazobactam (56%) or cefepime (32%). Antimicrobial therapy was longer in the control group than in the policy compliant group, 10 (IQR 7-16) vs. 19 days (IQR 15-23), P = 0.0001. After antibiotics discontinuation, 20% patients experienced fever recurrence, within 5.5 days (IQR 3-7.5). None of these febrile episodes were severe and 80% patients remained afebrile, with neutrophil recovery occurring within 5 days (IQR 2-8.5). Overall, 287 antibiotics days were spared; this represents 49% of all days with antibiotics. No patient had died at day 30 from intervention; six died during late follow-up, two from graft-versus-host disease and four from relapsed or refractory leukaemia. CONCLUSIONS Discontinuing antibiotics in neutropenic AML patients treated for a first episode of FN is safe, and results in significant antibiotic sparing.
Collapse
Affiliation(s)
- Zoé Van de Wyngaert
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France.
| | - Céline Berthon
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France; INSERM, UMR-S 1172; Institut pour la recherche sur le Cancer de Lille, Place de Verdun, F-59000 Lille France
| | - Houria Debarri
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Claire Bories
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Sarah Bonnet
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Morgane Nudel
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Benjamin Carpentier
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Charline Legrand
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Sarah Barbieux
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Paul Chauvet
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Arthur Simonnet
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Alexandre Willaume
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Jean-Baptiste Bossard
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Loic Renaud
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Kevin James Wattebled
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Guillaume Escure
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Nicolas Branche
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Ines Arib
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France
| | - Marie Titecat
- Service de bactériologie, Centre de biologie-pathologie, Rue du Pr Jules LECLERCQ, CHU de Lille, France
| | - Bruno Quesnel
- CHU Lille, Service des Maladies du Sang, Rue Michel Polonovski F-59000 Lille, France; INSERM, UMR-S 1172; Institut pour la recherche sur le Cancer de Lille, Place de Verdun, F-59000 Lille France; Univ. Lille, 2 Avenue Eugène Avinée, F-59000 Lille, France
| | - Serge Alfandari
- Service de réanimation et maladies infectieuses, CH Tourcoing, 59208 Tourcoing, France
| |
Collapse
|
22
|
Touzet L, Dumezy F, Roumier C, Berthon C, Bories C, Quesnel B, Preudhomme C, Boyer T. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med 2019; 8:1279-1288. [PMID: 30740913 PMCID: PMC6434215 DOI: 10.1002/cam4.2007] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 12/14/2018] [Accepted: 01/15/2019] [Indexed: 01/04/2023] Open
Abstract
CD9 is a cell surface protein and belongs to the tetraspanin family. Its role in carcinomagenesis has been widely studied in solid tumors but remains controversial, depending on the cancer type. Although CD9 seems to be associated with unfavorable outcome and disease progression in acute lymphoblastic leukemia (ALL), this marker has not yet been studied in acute myeloid leukemia (AML). First, we explored its prognostic role and its association with biological factors in a cohort of 112 AML patients treated with intensive chemotherapy. CD9 was expressed in 40% of AML and was associated with a favorable outcome (event‐free survival and relapse‐free survival) in univariate (P = 0.009 and P = 0.048, respectively) and multivariate (P = 0.004 and P = 0.039, respectively) analyses. Interestingly, CD9 expression was different between the more immature physiologic and AML cells (CD34+CD38−) as it was also expressed in AML on putative leukemic stem cells (LSCs) but not on hematopoietic stem cells (HSCs). Hence, CD9 could be a very relevant marker for minimal residual disease (MRD) monitoring in AML based on LSC targeting.
Collapse
Affiliation(s)
- Lucas Touzet
- Laboratory of Hematology, CHU Lille, Lille, France
| | | | | | | | | | | | | | - Thomas Boyer
- Laboratory of Hematology, CHU Lille, Lille, France
| |
Collapse
|
23
|
Renaud L, Nibourel O, Marceau-Renaut A, Gruson B, Cambier N, Lionne-Huyghe P, Choufi B, Rodriguez C, Frimat C, Plantier I, Stalnikiewicz L, Bemba M, Berthon C, Marolleau JP, Quesnel B, Preudhomme C, Duployez N. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory. Am J Hematol 2019; 94:E24-E27. [PMID: 30358899 DOI: 10.1002/ajh.25328] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 10/17/2018] [Accepted: 10/20/2018] [Indexed: 11/05/2022]
Affiliation(s)
- Loïc Renaud
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | - Olivier Nibourel
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | - Alice Marceau-Renaut
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | | | - Nathalie Cambier
- Department of Hematology; Hôpital St Vincent; Lille France
- Department of Hematology; CH Valenciennes; Valenciennes France
| | | | - Bachra Choufi
- Department of Hematology; CH Boulogne-sur-mer; Boulogne-sur-mer France
| | | | | | | | | | - Maxime Bemba
- Department of Hematology; CH Dunkerque; Dunkerque France
| | - Céline Berthon
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | | | - Bruno Quesnel
- Department of Hematology; CHU Lille; Lille France
- Inserm, UMR-S 1172; Lille France
| | - Claude Preudhomme
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| | - Nicolas Duployez
- Inserm, UMR-S 1172; Lille France
- Laboratory of Hematology; CHU Lille; Lille France
| |
Collapse
|
24
|
Drevon L, Marceau A, Maarek O, Cuccuini W, Clappier E, Eclache V, Cluzeau T, Richez V, Berkaoui I, Dimicoli-Salazar S, Bidet A, Vial JP, Park S, Vieira Dos Santos C, Kaphan E, Berthon C, Stamatoullas A, Delhommeau F, Abermil N, Braun T, Sapena R, Lusina D, Renneville A, Adès L, Raynaud S, Fenaux P. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies. Br J Haematol 2018; 182:843-850. [DOI: 10.1111/bjh.15490] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 05/25/2018] [Indexed: 11/28/2022]
Affiliation(s)
- Louis Drevon
- Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); University Paris Diderot (Paris 7); Paris France
| | - Alice Marceau
- Centre Hospitalier Régional Universitaire (CHRU) de Lille; Lille France
| | - Odile Maarek
- Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); University Paris Diderot (Paris 7); Paris France
| | - Wendy Cuccuini
- Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); University Paris Diderot (Paris 7); Paris France
| | - Emmanuelle Clappier
- Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); University Paris Diderot (Paris 7); Paris France
| | | | - Thomas Cluzeau
- Centre Hospitalier Universitaire (CHU) de Nice; Nice France
| | | | - Inès Berkaoui
- Centre Hospitalier Universitaire (CHU) de Nice; Nice France
| | | | | | | | | | | | | | - Céline Berthon
- Centre Hospitalier Régional Universitaire (CHRU) de Lille; Lille France
| | | | - François Delhommeau
- Hôpital Saint-Antoine; APHP; University Pierre et Marie Curie (Paris 6); Paris France
| | - Nassera Abermil
- Hôpital Saint-Antoine; APHP; University Pierre et Marie Curie (Paris 6); Paris France
| | - Thorsten Braun
- Hôpital Avicenne; APHP; University Paris 13; Bobigny France
| | - Rosa Sapena
- GFM (Groupe Francophone des Myélodysplasies); Hôpital Saint-Louis; Paris France
| | - Daniel Lusina
- Hôpital Avicenne; APHP; University Paris 13; Bobigny France
| | - Aline Renneville
- Centre Hospitalier Régional Universitaire (CHRU) de Lille; Lille France
| | - Lionel Adès
- Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); University Paris Diderot (Paris 7); Paris France
| | - Sophie Raynaud
- Centre Hospitalier Universitaire (CHU) de Nice; Nice France
| | - Pierre Fenaux
- Hôpital Saint-Louis; Assistance Publique Hôpitaux de Paris (APHP); University Paris Diderot (Paris 7); Paris France
| |
Collapse
|
25
|
Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. Br J Haematol 2018; 181:350-359. [DOI: 10.1111/bjh.15190] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Accepted: 01/29/2018] [Indexed: 11/29/2022]
Affiliation(s)
- María Díez-Campelo
- Haematology, Hospital Universitario de Salamanca; Salamanca Spain
- Institute of Biomedical Research of Salamanca (IBSAL); Salamanca Spain
| | - Jose I. Lorenzo
- Haematology Department; Hospital Universitario y Politécnico La Fe; Valencia Spain
| | - Raphael Itzykson
- Service d'Hematologie; St Louis, assistance publique hôpitaux de Paris and Paris Diderot University; Paris France
| | - Silvia M. Rojas
- Haematology, Hospital Universitario de Salamanca; Salamanca Spain
| | - Céline Berthon
- Maladies du Sang; Hopital Huriez; CHRU de Lille; Lille France
| | - Elisa Luño
- Haematology; Hospital Universitario Central de Asturias; Oviedo Spain
| | | | | | - Norbert Vey
- Haematology department; Institut Paoli Calmettes; Marseille France
| | - Joan Bargay
- Hospital Sont Llatzer; Palma de Mallorca Spain
| | - Sophie Park
- Haematology; Clinique Universitaire d′Hématologie; CHU de Grenoble; Grenoble France
| | | | - Dominique Bordessoule
- Unité de Recherche Clinique; Service d'Hématologie Clinique et Thérapie Cellulaire; Limoges France
| | | | - Emmanuel Gyan
- Service d'hématologie et thérapie cellulaire; CHRU de Tours; Team 3 UMR CNRS 7292; Université François Rabelais; Tours France
| | - Esperanza Such
- Haematology Department; Hospital Universitario y Politécnico La Fe; Valencia Spain
| | - Sorin Visanica
- Hématologie - Hôpital Bon Secours; Metz-Thionville; Thionville France
| | | | | | - Jesús M. Hernández-Rivas
- Haematology, Hospital Universitario de Salamanca; Salamanca Spain
- Institute of Biomedical Research of Salamanca (IBSAL); Salamanca Spain
| | - Shanti Ame
- Haematology Department; Hôpital Civil; Strasbourg France
| | | | | | | | - Françoise Isnard
- Department of Haematology; Assistance Publique-Hopitaux de Paris (AP-HP) Saint-Antoine; Universite Pierre et Marie Curie; Paris France
| | | | - Joan Pérez Guallar
- Department of application statistics; Universidad Autónoma de Barcelona; Barcelona Spain
| | - Llorenc Badiella
- Department of application statistics; Universidad Autónoma de Barcelona; Barcelona Spain
| | - Guillermo Sanz
- Haematology Department; Hospital Universitario y Politécnico La Fe; Valencia Spain
| | - Consuelo Cañizo
- Haematology, Hospital Universitario de Salamanca; Salamanca Spain
- Institute of Biomedical Research of Salamanca (IBSAL); Salamanca Spain
| | - Pierre Fenaux
- Service d'Hematologie; St Louis, assistance publique hôpitaux de Paris and Paris Diderot University; Paris France
| |
Collapse
|
26
|
Bonnet S, Duléry R, Regany K, Bouketouche M, Magro L, Coiteux V, Alfandari S, Berthon C, Quesnel B, Yakoub-Agha I. Long-term follow up of invasive aspergillosis in allogeneic stem cell transplantation recipients and leukemia patients: Differences in risk factors and outcomes. Curr Res Transl Med 2017; 65:77-81. [PMID: 28689016 DOI: 10.1016/j.retram.2017.05.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Revised: 05/22/2017] [Accepted: 05/31/2017] [Indexed: 11/30/2022]
Abstract
Antifungal prophylaxis (AP) has dramatically changed the epidemiology of invasive aspergillosis (IA). To better understand the differences in terms of clinical significance of IA between allogeneic stem cell transplantation (allo-SCT) recipients and patients treated for leukemia, we report a single-center study of 735 unselected consecutive patients treated between 2000 and 2004, before the era of systematic AP. Probable or confirmed IA were observed in 29 patients (2008 EORTC/MSG criteria), including 7/235 undergoing allo-SCT (5.2%), 19/380 treated for acute leukemia (5.0%), 1/116 for chronic lymphocytic leukemia (0.9%) and 2/104 for myelodysplastic syndrome (1.9%). In allo-SCT recipients, IA occurred later than in leukemia patients, after the neutropenic period. The median time between the last treatment and the diagnosis of IA was 231 days (range, 68-341) in allo-SCT recipients and 17 days (6-57) in leukemia patients (P<0.001). Importantly, the 7 cases of IA after allo- SCT occurred only in patients treated with corticosteroids for graft-versus-host disease (GVHD). Mortality directly related to IA was 24%. The 100-day, 2-year and 10-year overall survival were 42.9%, 0%, 0% in allo-SCT recipients compared to 68.1%, 18.2%, 13.6% in leukemia patients, respectively (P≥0.05). These poor outcomes were mainly attributable to non-relapse mortality (NRM). In conclusion, our data allows distinguishing 2 types of IA occurring at different time in the treatment course. In both cases, the NRM is very high and treatment remains challenging. Thus, systematic broad-spectrum AP against Aspergillus should be considered in acute leukemia patients during the neutropenic phase and in all patients undergoing allo-SCT who develop GVHD.
Collapse
Affiliation(s)
- S Bonnet
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - R Duléry
- Department of Hematology, CHRU Saint-Antoine, AP-HP, 75012 Paris, France.
| | - K Regany
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - M Bouketouche
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - L Magro
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - V Coiteux
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - S Alfandari
- Department of infectious Diseases, Dron Hospital, 59200 Tourcoing, France.
| | - C Berthon
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - B Quesnel
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| | - I Yakoub-Agha
- Department of Hematology, CHRU de Lille, 59037 Lille, France.
| |
Collapse
|
27
|
Drevon L, Renneville A, Marceau A, Raynaud S, Maarek O, Dimicoli-Salazar S, Cuccuini W, Bidet A, Eclache V, Lusina D, Park S, Stamatoullas A, Delhommeau F, Berthon C, Berkaoui I, Richez V, Vieira Dos Santos C, Braun T, Ades L, Fenaux P. MDS with Isolated Trisomy 8: A type of MDS Frequently Associated with Myeloproliferative Features? A Report by the GFM. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30146-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
28
|
Díez Campelo M, Lorenzo J, Itzykson R, Rojas S, Berthon C, Pérez-Oteiza J, Beyne-Rauzy O, Bargay J, Vey N, Cedena T, Park S, Such E, Bordessoule D, Hernández Rivas J, López Cadenas F, Cañizo M, Fenaux P. Azacitidine Improves Outcome in High Risk MDS Patients with Chromosome 7 Abnormalities: Retrospective Comparison of GESMD and GFM Registries. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30211-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Alfandari S, Berthon C, Ader F. Carbapenems and febrile neutropenia. Clin Microbiol Infect 2017; 23:212-213. [DOI: 10.1016/j.cmi.2016.12.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 12/10/2016] [Indexed: 11/28/2022]
|
30
|
Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol 2017; 35:1223-1230. [PMID: 28221862 DOI: 10.1200/jco.2016.70.4551] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA) versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acute myeloid leukemia (AML). Patients and Methods Patients age 18 to 59 years old with intermediate- or unfavorable-risk AML in first remission and no identified donor for allogeneic stem-cell transplantation (SCT) were eligible. Two hundred twenty-one patients were randomly assigned to receive three CLARA or three HDAC consolidation cycles. The primary end point was relapse-free survival (RFS). To handle the confounding effect of SCT that could occur in patients with late donor identification, hazard ratios (HRs) of events were adjusted on the time-dependent treatment × SCT interaction term. Results At 2 years, RFS was 58.5% (95% CI, 49% to 67%) in the CLARA arm and 46.5% (95% CI, 37% to 55%) in the HDAC arm. Overall, 110 patients (55 in each arm) received SCT in first remission. On the basis of a multivariable Cox-adjusted treatment × SCT interaction, the HR of CLARA over HDAC before or in absence of SCT was 0.65 (95% CI, 0.43 to 0.98; P = .041). In a sensitivity analysis, when patients who received SCT in first remission were censored at SCT time, 2-year RFS was 53.3% (95% CI, 39% to 66%) in the CLARA arm and 31.0% (95% CI, 19% to 43%) in the HDAC arm (HR, 0.63; 95% CI, 0.41 to 0.98; P = .043). Gain in RFS could be related to the lower cumulative incidence of relapse observed in the CLARA arm versus the HDAC arm (33.9% v 46.4% at 2 years, respectively; cause-specific HR, 0.61; 95% CI, 0.40 to 0.94; P = .025). CLARA cycles were associated with higher hematologic and nonhematologic toxicity than HDAC cycles. Conclusion These results suggest that CLARA might be considered as a new chemotherapy option in younger patients with AML in first remission.
Collapse
Affiliation(s)
- Xavier Thomas
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Stéphane de Botton
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Sylvie Chevret
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Denis Caillot
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Emmanuel Raffoux
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Emilie Lemasle
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Jean-Pierre Marolleau
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Céline Berthon
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Arnaud Pigneux
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Norbert Vey
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Oumedaly Reman
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Marc Simon
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Christian Recher
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Jean-Yves Cahn
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Olivier Hermine
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Sylvie Castaigne
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Karine Celli-Lebras
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Norbert Ifrah
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Claude Preudhomme
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Christine Terré
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| | - Hervé Dombret
- Xavier Thomas, Lyon-Sud University Hospital, Pierre Bénite; Stéphane de Botton, Gustave-Roussy Cancer Institute, Villejuif; Sylvie Chevret, Emmanuel Raffoux, and Hervé Dombret, Paris Saint-Louis University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University Paris Diderot; Olivier Hermine, Paris Necker University Hospital, AP-HP, University Paris Descartes; Karine Celli-Lebras, Acute Leukemia French Association Coordination Office, Paris Saint-Louis University Hospital, Paris; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Cancer Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Céline Berthon, Claude Huriez University Hospital; Claude Preudhomme, University of Lille, Claude Huriez University Hospital, Institut National de la Santé et de la Recherche Médicale UMR-S 1172, Jean-Pierre Aubert Research Institute, Lille; Arnaud Pigneux, Bordeaux Haut-Leveque University Hospital, Pessac; Norbert Vey, Paoli-Calmette Cancer Institute, Marseille; Oumedaly Reman, George-Clémenceau University Hospital, Caen; Marc Simon, Valenciennes Hospital, Valenciennes; Christian Recher, Toulouse Cancer University Institute, Toulouse; Jean-Yves Cahn, Grenoble University Hospital, Grenoble; Sylvie Castaigne and Christine Terré, Versailles University Hospital, Versailles-Saint Quentin University, Le Chesnay; and Norbert Ifrah, Angers University Hospital, Angers, France
| |
Collapse
|
31
|
Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol 2016; 35:185-193. [PMID: 28056203 DOI: 10.1200/jco.2016.67.1875] [Citation(s) in RCA: 193] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed the question of whether NPM1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit. Patients and Methods Among 229 patients with NPM1m who were treated in the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 patients in first remission. Patients with nonfavorable AML according to the European LeukemiaNet (ELN) classification were eligible for ASCT in first remission. Results After induction therapy, patients who did not achieve a 4-log reduction in NPM1m peripheral blood-MRD (PB-MRD) had a higher cumulative incidence of relapse (subhazard ratio [SHR], 5.83; P < .001) and a shorter overall survival (OS; hazard ratio [HR], 10.99; P < .001). In multivariable analysis, an abnormal karyotype, the presence of FLT3-internal tandem duplication (ITD), and a < 4-log reduction in PB-MRD were significantly associated with a higher relapse incidence and shorter OS. In the subset of patients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD, but not FLT3-ITD allelic ratio, remained of significant prognostic value. In these patients with nonfavorable AML according to European LeukemiaNet, disease-free survival and OS were significantly improved by ASCT in those with a < 4-log reduction in PB-MRD. This benefit was not observed in those with a > 4-log reduction in PB-MRD, with a significant interaction between ASCT effect and PB-MRD response ( P = .024 and .027 for disease-free survival and OS, respectively). Conclusion Our study supports the strong prognostic significance of early NPM1m PB-MRD, independent of the cytogenetic and molecular context. Moreover, NPM1m PB-MRD may be used as a predictive factor for ASCT indication.
Collapse
Affiliation(s)
- Marie Balsat
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Aline Renneville
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Xavier Thomas
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Stéphane de Botton
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Denis Caillot
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Alice Marceau
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Emilie Lemasle
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Jean-Pierre Marolleau
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Olivier Nibourel
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Céline Berthon
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Emmanuel Raffoux
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Arnaud Pigneux
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Céline Rodriguez
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Norbert Vey
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Jean-Michel Cayuela
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Sandrine Hayette
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Thorsten Braun
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Marie Magdeleine Coudé
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Christine Terre
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Karine Celli-Lebras
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Hervé Dombret
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Claude Preudhomme
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| | - Nicolas Boissel
- Marie Balsat, Xavier Thomas, and Sandrine Hayette, Centre Hospitalier Lyon Sud, Pierre Benite; Aline Renneville, Alice Marceau, Olivier Nibourel, Céline Rodriguez, and Claude Preudhomme, CHRU of Lille; Aline Renneville, Alice Marceau, Olivier Nibourel, and Claude Preudhomme, Cancer Research Institute of Lille and Université Lille; and Céline Berthon, Claude Huriez Hospital, Lille; Stéphane de Botton, Institut Gustave Roussy, Villejuif; Denis Caillot, Dijon University Hospital, Dijon; Emilie Lemasle, Henri-Becquerel Center, Rouen; Jean-Pierre Marolleau, Amiens University Hospital, Amiens; Emmanuel Raffoux, Hervé Dombret, Jean-Michel Cayuela, Marie Magdeleine Coudé, Karine Celli-Lebras, and Nicolas Boissel, Hôpital Saint-Louis, AP-HP; Emmanuel Raffoux, Herve Dombret, and Nicolas Boissel, University 7 Paris Diderot; and Thorsten Braun, Hôpital Avicennes, AP-HP, Paris; Arnaud Pigneux, Haut-Leveque Hospital, Pessac; Norbert Vey, Paoli-Calmette Institute, Marseille; and Christine Terre, Hôpital de Versailles, Le Chesnay, France
| |
Collapse
|
32
|
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget 2016; 6:42345-53. [PMID: 26486081 PMCID: PMC4747230 DOI: 10.18632/oncotarget.5645] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 10/02/2015] [Indexed: 12/18/2022] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be determined which molecular markers are the most suitable for MRD monitoring. Recent advances in next-generation sequencing (NGS) have provided the opportunity to use multiple molecular markers. In this study, we used NGS technology to assess MRD in 31 AML patients enrolled in the ALFA-0701 trial and harboring NPM1 mutations associated to IDH1/2 or DNMT3A mutations. NPM1 mutation-based MRD monitoring was performed by RTqPCR. IDH1/2 and DNMT3A mutations were quantified by NGS using an Ion Torrent Proton instrument with high coverage (2 million reads per sample). The monitoringof IDH1/2 mutations showed that these mutations were reliable MRD markers that allowed the prediction of relapse in the majority of patients. Moreover, IDH1/2 mutation status predicted relapse or disease evolution in 100% of cases if we included the patient who developed myelodysplastic syndrome. In contrast, DNMT3A mutations were not correlated to the disease status, as we found that a preleukemic clone with DNMT3A mutation persisted in 40% of the patients who were in complete remission, reflecting the persistence of clonal hematopoiesis.
Collapse
Affiliation(s)
- Houria Debarri
- Hematology Department, Lille University Hospital, Lille, France.,Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France
| | - Delphine Lebon
- Hematology Department, Amiens University Hospital, Amiens, France
| | - Christophe Roumier
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Meyling Cheok
- UMR-S 1172, Team 3, INSERM, Lille, France.,Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Alice Marceau-Renaut
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Olivier Nibourel
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Sandrine Geffroy
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Nathalie Helevaut
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France
| | | | - Bérengère Gruson
- Hematology Department, Amiens University Hospital, Amiens, France
| | - Claude Gardin
- Hematology Department, Avicenne Hospital, APHP, University Paris 13, Bobigny, France
| | | | - Shéhérazade Sebda
- Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Martin Figeac
- Functional Genomic Platform, Cancer Research Institute, Lille, France
| | - Céline Berthon
- Hematology Department, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Bruno Quesnel
- Hematology Department, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Nicolas Boissel
- Hematology Department, Saint-Louis Hospital, APHP, Paris, France
| | | | - Hervé Dombret
- Hematology Department, Saint-Louis Hospital, APHP, Paris, France
| | - Aline Renneville
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| | - Claude Preudhomme
- Hematology Laboratory, Biology and Pathology Center, Lille University Hospital, Lille, France.,UMR-S 1172, Team 3, INSERM, Lille, France
| |
Collapse
|
33
|
Demarquette H, Nudel M, Gauthier J, Bonnet S, Delvallez G, Le Grand C, Berthon C, Yakoub-Agha I, Lemaitre N, Alfandari S. BMR-03 - Facteurs de risque de bactériémie à BLSE chez les patients colonisés à BLSE en hématologie. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30312-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
34
|
Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. The Lancet Haematology 2016; 3:e186-95. [DOI: 10.1016/s2352-3026(15)00247-1] [Citation(s) in RCA: 264] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 11/03/2015] [Accepted: 11/04/2015] [Indexed: 01/07/2023]
|
35
|
Duployez N, Nibourel O, Ducourneau B, Grardel N, Boyer T, Bories C, Darre S, Coiteux V, Berthon C, Preudhomme C, Roche-Lestienne C. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm withBCR-JAK2fusion transcript. Eur J Haematol 2016; 97:399-402. [DOI: 10.1111/ejh.12752] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/29/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Nicolas Duployez
- CHU Lille; Biology and Pathology Center; Institute of Hematology; Lille France
- INSERM UMR-S 1172; Cancer Research Institute; Lille France
| | - Olivier Nibourel
- CHU Lille; Biology and Pathology Center; Institute of Hematology; Lille France
- INSERM UMR-S 1172; Cancer Research Institute; Lille France
| | - Benoît Ducourneau
- CHU Lille; Biology and Pathology Center; Institute of Hematology; Lille France
| | - Nathalie Grardel
- CHU Lille; Biology and Pathology Center; Institute of Hematology; Lille France
| | - Thomas Boyer
- CHU Lille; Biology and Pathology Center; Institute of Hematology; Lille France
- INSERM UMR-S 1172; Cancer Research Institute; Lille France
| | - Claire Bories
- Department of Hematology; CHU Lille; Claude Huriez Hospital; Lille France
| | | | - Valérie Coiteux
- Department of Hematology; CHU Lille; Claude Huriez Hospital; Lille France
| | - Céline Berthon
- INSERM UMR-S 1172; Cancer Research Institute; Lille France
- Department of Hematology; CHU Lille; Claude Huriez Hospital; Lille France
| | - Claude Preudhomme
- CHU Lille; Biology and Pathology Center; Institute of Hematology; Lille France
- INSERM UMR-S 1172; Cancer Research Institute; Lille France
| | - Catherine Roche-Lestienne
- INSERM UMR-S 1172; Cancer Research Institute; Lille France
- CHU Lille; Jeanne de Flandre Hospital; Institute of Medical Genetics; Lille France
| |
Collapse
|
36
|
Le Guern A, Becquart C, Desmedt E, Berthon C, Delaporte E, Staumont-Sallé D. Quand la toxidermie n’est pas limitée aux extrémités. Ann Dermatol Venereol 2015. [DOI: 10.1016/j.annder.2015.10.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
37
|
Desoutter J, Gay J, Berthon C, Ades L, Gruson B, Geffroy S, Plantier I, Marceau A, Helevaut N, Fernandes J, Bemba M, Stalnikiewicz L, Frimat C, Labreuche J, Nibourel O, Roumier C, Figeac M, Fenaux P, Quesnel B, Renneville A, Duhamel A, Preudhomme C. Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine. Leukemia 2015; 30:1416-8. [PMID: 26582646 DOI: 10.1038/leu.2015.314] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- J Desoutter
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Gay
- Service d'hématologie clinique, Hôpital Saint Antoine, Université Paris 6, APHP, Paris, France
| | - C Berthon
- Service d'hématologie clinique, CHRU Lille, Université Lille 2, Lille, France
| | - L Ades
- Service d'hématologie clinique, Hôpital d'Avicenne, Université Paris 13, Bobigny, France
| | - B Gruson
- Service d'hématologie clinique, CHU Amiens-Picardie, Amiens, France
| | - S Geffroy
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - I Plantier
- Service d'hématologie clinique, Hôpital de Roubaix, Roubaix, France
| | - A Marceau
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - N Helevaut
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Fernandes
- Service d'hématologie clinique, Hôpital de Valenciennes, Valenciennes, France
| | - M Bemba
- Service d'hématologie clinique, Hôpital de Dunkerque, Dunkerque, France
| | - L Stalnikiewicz
- Service d'hématologie clinique, Hôpital de Lens, Lens, France
| | - C Frimat
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - J Labreuche
- Unités de Biostatistiques, CHRU Lille, Université Lille 2, Lille, France
| | - O Nibourel
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - C Roumier
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - M Figeac
- Plateforme de génomique structurale et fonctionnelle, IFR-114, Université Lille 2, Lille, France
| | - P Fenaux
- Service d'hématologie clinique, Hôpital Saint-Louis, Université Paris 7, APHP, Paris, France
| | - B Quesnel
- Service d'hématologie clinique, CHRU Lille, Université Lille 2, Lille, France
| | - A Renneville
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| | - A Duhamel
- Unités de Biostatistiques, CHRU Lille, Université Lille 2, Lille, France
| | - C Preudhomme
- Laboratoire d'hématologie, Centre de Biologie Pathologie, CHRU Lille, Université Lille 2, Lille, France
| |
Collapse
|
38
|
Wanquet A, Prebet T, Berthon C, Sebert M, Roux C, Kulasekararaj A, Micol JB, Esterni B, Itzykson R, Thepot S, Recher C, Delaunay J, Dreyfus F, Mufti G, Fenaux P, Vey N. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Am J Hematol 2015; 90:859-63. [PMID: 26113240 DOI: 10.1002/ajh.24099] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 06/22/2015] [Indexed: 12/26/2022]
Abstract
Acute Myeloid Leukemia (AML) and myelodysplasia (MDS) with chromosome 3q abnormalities have a dismal outcome either untreated or with conventional treatments. Azacitidine (AZA) is now considered as the standard of care in high-risk MDS and oligoblastic AML patients. The objective of this study was to evaluate the impact of azacitine treatment in this cytogenetic subgroup. We report here a multicentre retrospective study of 157 patients treated with AZA for AML/MDS with chromosome 3q abnormalities and 27 patients with isolated EVI-1 overexpression. Median age was 65 years, 40 patients (25%) had inv(3)(q21q26.2) or t(3;3)(q21;q26.2), 36 patients (23%) had other balanced 3q26 rearrangements, 8 patients (5%) had balanced 3q21 rearrangements and 73 patients (46%) had other 3q abnormalities. The overall response rate was 50% (29% CR). Median overall survival was 10.6 months. By multivariate analysis, patients with lower bone marrow blast counts, higher platelet counts, non-complex cytogenetics, and absence of prior treatment with intensive chemotherapy had a better outcome. 27 patients were allo-transplanted and achieved a 21-month median OS. Balanced 3q21 translocations were associated with a better response rate and overall survival. Outcome of patients with isolated EVI-1 overexpression was comparable to that of patients with chromosome 3q lesions. Thus, AML/MDS patients with 3q abnormalities appear to be a heterogeneous group in their response to AZA, and AZA may represent a suitable option in particular as a bridge to allogeneic transplantation.
Collapse
Affiliation(s)
- Anne Wanquet
- Hematology Department; Institut Paoli-Calmettes; Marseille France
| | - Thomas Prebet
- Hematology Department; Institut Paoli-Calmettes; Marseille France
| | - Céline Berthon
- Hematology Department; Centre Hospitalo Universitaire De Lille; Lille France
| | - Marie Sebert
- Hematology Department; Assistance Publique-Hôpitaux De Paris (APHP), Hopital Saint Louis, Paris and Paris 7 University; France
| | - Clémence Roux
- Hematology Department; Centre Hospitalo Universitaire De Nice; Nice France
| | | | | | - Benjamin Esterni
- Biostatistics Department; Institut paoli-Calmettes; Marseille France
| | - Raphael Itzykson
- Hematology Department; Assistance Publique-Hôpitaux De Paris (APHP), Hopital Saint Louis, Paris and Paris 7 University; France
| | - Sylvain Thepot
- Hematology Department; Hopital Avicenne (APHP) and Paris 13 University; Bobigny France
| | - Christian Recher
- Hematology Department; Centre Hospitalo Universitaire De Toulouse; Toulouse France
| | - Jacques Delaunay
- Hematology Department; Centre Hospitalo Universitaire De Nantes; Nantes France
| | - François Dreyfus
- Hematology Department; Hopital Cochin (APHP) and Paris 5 University; Paris France
| | - Ghulam Mufti
- Hematology Department; King's College; London United Kingdom
| | - Pierre Fenaux
- Hematology Department; Assistance Publique-Hôpitaux De Paris (APHP), Hopital Saint Louis, Paris and Paris 7 University; France
| | - Norbert Vey
- Hematology Department; Institut Paoli-Calmettes; Marseille France
- Aix Marseille University; Marseille France
| |
Collapse
|
39
|
Campelo MD, Lorenzo J, Itzykson R, Rojas S, Berthon C, Luño E, Beyne-Rauzy O, Pérez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz J, Gyan E, Such E, Visanica S, Benlloch L, de Botton S, Hernández-Rivas J, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Sanz G, Cañizo M, Fenaux P. 213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30214-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
40
|
Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 2015; 100:780-5. [PMID: 25715404 DOI: 10.3324/haematol.2014.114884] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2014] [Accepted: 02/19/2015] [Indexed: 01/23/2023] Open
Abstract
Core-binding factor acute myeloid leukemia is a favorable acute myeloid leukemia subset cytogenetically defined by t(8;21) or inv(16)/t(16;16) rearrangements, disrupting RUNX1 (previously CBFA/AML1) or CBFB transcription factor functions. The receptor tyrosine kinase KIT is expressed in the vast majority of these acute myeloid leukemias and frequent activating KIT gene mutations have been associated with a higher risk of relapse. This phase II study aimed to evaluate dasatinib as maintenance therapy in patients with core-binding factor acute myeloid leukemia in first hematologic complete remission, but at higher risk of relapse due to molecular disease persistence or recurrence. A total of 26 patients aged 18-60 years old previously included in the CBF-2006 trial were eligible to receive dasatinib 140 mg daily if they had a poor initial molecular response (n=18) or a molecular recurrence (n=8). The tolerance of dasatinib as maintenance therapy was satisfactory. The 2-year disease-free survival in this high-risk population of patients was 25.7%. All but one patient with molecular recurrence presented subsequent hematologic relapse. Patients with slow initial molecular response had a similar disease-free survival when treated with dasatinib (40.2% at 2 years) or without any maintenance (50.0% at 2 years). The disappearance of KIT gene mutations at relapse suggests that clonal devolution may in part explain the absence of efficacy observed with single-agent dasatinib in these patients (n. EudraCT: 2006-006555-12).
Collapse
Affiliation(s)
- Nicolas Boissel
- Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris EA-3518, Université Paris 7
| | - Aline Renneville
- Laboratoire d'hématologie, Centre de Biologie-Pathologie, CHRU de Lille Equipe 3 INSERM U837, JPARC Lille
| | | | | | | | - Thibaud Lecerf
- Service des Maladies du Sang, INSERM U892/CNRS 6299, CHU Angers
| | | | | | | | - Thomas Prebet
- Service d'Hématologie, Institut Paoli Calmettes, Marseille
| | | | | | | | | | | | | | | | | | - Claude Preudhomme
- Laboratoire d'hématologie, Centre de Biologie-Pathologie, CHRU de Lille Equipe 3 INSERM U837, JPARC Lille
| | - Eric Jourdan
- Hématologie Clinique et Oncologie Médicale, CHU de Nîmes, France
| | - Hervé Dombret
- Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris EA-3518, Université Paris 7
| | - Norbert Ifrah
- Service des Maladies du Sang, INSERM U892/CNRS 6299, CHU Angers
| |
Collapse
|
41
|
Itzykson R, Thépot S, Berthon C, Delaunay J, Bouscary D, Cluzeau T, Turlure P, Prébet T, Dartigeas C, Marolleau JP, Recher C, Plantier I, Stamatoullas A, Devidas A, Taksin AL, Guièze R, Caillot D, Vey N, Adès L, Ifrah N, Dombret H, Fenaux P, Gardin C. Azacitidine for the treatment of relapsed and refractory AML in older patients. Leuk Res 2015; 39:124-30. [DOI: 10.1016/j.leukres.2014.11.009] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 10/31/2014] [Accepted: 11/14/2014] [Indexed: 01/07/2023]
|
42
|
Willekens C, Dumezy F, Boyer T, Renneville A, Rossignol J, Berthon C, Cotteau-Leroy A, Mehiaoui L, Quesnel B, Preudhomme C. Linezolid induces ring sideroblasts. Haematologica 2014; 98:e138-40. [PMID: 24186315 DOI: 10.3324/haematol.2013.092395] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
43
|
Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M, Berthon C, Terriou L, Coiteux V, Macro M, Decaux O, Facon T, Huglo D, Leleu X. Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma. Clin Cancer Res 2014; 20:3254-60. [DOI: 10.1158/1078-0432.ccr-13-2910] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Janin M, Mylonas E, Saada V, Micol JB, Renneville A, Quivoron C, Koscielny S, Scourzic L, Forget S, Pautas C, Caillot D, Preudhomme C, Dombret H, Berthon C, Barouki R, Rabier D, Auger N, Griscelli F, Chachaty E, Leclercq E, Courtier MH, Bennaceur-Griscelli A, Solary E, Bernard OA, Penard-Lacronique V, Ottolenghi C, de Botton S. Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. J Clin Oncol 2014; 32:297-305. [DOI: 10.1200/jco.2013.50.2047] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Purpose Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high levels of 2-hydroxyglutarate (2-HG). We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence of IDH1/2 mutations at diagnosis and provide a marker of minimal residual disease (MRD). Patients and Methods Serum samples from 82 patients at diagnosis of de novo AML (IDH1/2 mutated, n = 53) and 68 patients without AML were analyzed for total 2-HG and its ratio of D to L stereoisomers by mass spectrometry. We measured 2-HG levels and molecular markers of MRD (WT1 and NPM1) in serial samples of 36 patients with IDH1/2 mutations after induction therapy. Results In patients with AML with IDH1/2 mutations, 2-HG serum levels were significantly higher than in patients with IDH1/2 wild type (P < .001). Area under the receiver operating characteristic curve was 99%. The optimum diagnostic cutoff between IDH1/2 mutated and normal was 2 μmol/L (sensitivity, 100%; specificity, 79%). Quantification of the D/L stereoisomers increased specificity (100%; 95% CI, 83% to 100%) compared with total 2-HG (P = .031). In patients with IDH2 R172 mutations, 2-HG levels were higher relative to those with other IDH1/2 mutations (P < .05). During follow-up, serum 2-HG levels showed strong positive correlation with WT1 and NPM1 (P < .001). After induction therapy, total 2-HG serum levels < 2 μmol/L were associated with better overall (P = .008) and disease-free survival (P = .005). Conclusion Serum 2-HG is a predictor of the presence of IDH1/2 mutations and outcome in these patients. Discrimination between D/L stereoisomers improved specificity.
Collapse
Affiliation(s)
- Maxime Janin
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Elena Mylonas
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Véronique Saada
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Jean-Baptiste Micol
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Aline Renneville
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Cyril Quivoron
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Serge Koscielny
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Laurianne Scourzic
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Sébastien Forget
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Cécile Pautas
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Denis Caillot
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Claude Preudhomme
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Hervé Dombret
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Céline Berthon
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Robert Barouki
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Daniel Rabier
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Nathalie Auger
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Frank Griscelli
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Elisabeth Chachaty
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Edwige Leclercq
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Marie-Hélène Courtier
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Annelise Bennaceur-Griscelli
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Eric Solary
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Olivier Adrien Bernard
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Virginie Penard-Lacronique
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Chris Ottolenghi
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| | - Stéphane de Botton
- Maxime Janin, Robert Barouki, Daniel Rabier, and Chris Ottolenghi, Biochimie Métabolique, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Necker-Enfants Malades; Maxime Janin, Robert Barouki, and Chris Ottolenghi, Institut National de la Santé et de la Recherche Médicale (INSERM) U747, Université Paris Descartes; Hervé Dombret, Hôpital Saint-Louis, Paris; Elena Mylonas, Cyril Quivoron, Laurianne Scourzic, Olivier Adrien Bernard, Virginie Penard-Lacronique, and Stéphane de Botton, INSERM U985,
| |
Collapse
|
45
|
Ben Abdelali R, Asnafi V, Petit A, Micol JB, Callens C, Villarese P, Delabesse E, Reman O, Lepretre S, Cahn JY, Guillerm G, Berthon C, Gardin C, Corront B, Leguay T, Béné MC, Ifrah N, Leverger G, Dombret H, Macintyre E. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica 2013; 98:1711-7. [PMID: 23831922 DOI: 10.3324/haematol.2013.086082] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
CALM-AF10 (also known as PICALM-MLLT10) is the commonest fusion protein in T-cell acute lymphoblastic leukemia, but its prognostic impact remains unclear. Molecular screening at diagnosis identified CALM-AF10 in 30/431 (7%) patients with T-cell acute lymphoblastic leukemia aged 16 years and over and in 15/234 (6%) of those aged up to 15 years. Adult CALM-AF10-positive patients were predominantly (72%) negative for surface (s)CD3/T-cell receptor, whereas children were predominantly (67%) positive for T-cell receptor. Among 22 adult CALM-AF10-positive patients treated according to the LALA94/GRAALL03-05 protocols, the poor prognosis for event-free survival (P=0.0017) and overall survival (P=0.0014) was restricted to the 15 T-cell receptor-negative cases. Among CALM-AF10-positive, T-cell receptor-negative patients, 82% had an early T-cell precursor phenotype, reported to be of poor prognosis in pediatric T-cell acute lymphoblastic leukemia. Early T-cell precursor acute lymphoblastic leukemia corresponded to 22% of adult LALA94/GRAALL03-05 T-cell acute lymphoblastic leukemias, but had no prognostic impact per se. CALM-AF10 fusion within early T-cell precursor acute lymphoblastic leukemia (21%) did, however, identify a group with a poor prognosis with regards to event-free survival (P=0.04). CALM-AF10 therefore identifies a poor prognostic group within sCD3/T-cell receptor negative adult T-cell acute lymphoblastic leukemias and is over-represented within early T-cell precursor acute lymphoblastic leukemias, in which it identifies patients in whom treatment is likely to fail. Its prognosis and overlap with early T-cell precursor acute lymphoblastic leukemia in pediatric T-cell acute lymphoblastic leukemia merits analysis. The clinical trial GRAALL was registered at Clinical Trials.gov number NCT00327678.
Collapse
|
46
|
Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, Berthon C, Adès L, Fenaux P, Beyne-Rauzy O, Vey N, Braun T, Haferlach T, Dreyfus F, Cross NC, Preudhomme C, Bernard OA, Fontenay M, Vainchenker W, Schnittger S, Birnbaum D, Droin N, Solary E. Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. J Clin Oncol 2013; 31:2428-36. [DOI: 10.1200/jco.2012.47.3314] [Citation(s) in RCA: 406] [Impact Index Per Article: 36.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Purpose Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations—including ASXL1—have been associated with poor prognosis in univariable analyses. We developed and validated a prognostic score for overall survival (OS) based on mutational status and standard clinical variables. Patients and Methods We genotyped ASXL1 and up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription (RUNX1, NPM1, TP53), and signaling (NRAS, KRAS, CBL, JAK2, FLT3) regulators in 312 patients with CMML. Genotypes and clinical variables were included in a multivariable Cox model of OS validated by bootstrapping. A scoring system was developed using regression coefficients from this model. Results ASXL1 mutations (P < .0001) and, to a lesser extent, SRSF2 (P = .03), CBL (P = .003), and IDH2 (P = .03) mutations predicted inferior OS in univariable analysis. The retained independent prognostic factors included ASXL1 mutations, age older than 65 years, WBC count greater than 15 ×109/L, platelet count less than 100 ×109/L, and anemia (hemoglobin < 10 g/dL in female patients, < 11g/dL in male patients). The resulting five-parameter prognostic score delineated three groups of patients with median OS not reached, 38.5 months, and 14.4 months, respectively (P < .0001), and was validated in an independent cohort of 165 patients (P < .0001). Conclusion A new prognostic score including ASXL1 status, age, hemoglobin, WBC, and platelet counts defines three groups of CMML patients with distinct outcomes. Based on concordance analysis, this score appears more discriminative than those based solely on clinical parameters.
Collapse
Affiliation(s)
- Raphaël Itzykson
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Olivier Kosmider
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Aline Renneville
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Véronique Gelsi-Boyer
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Manja Meggendorfer
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Margot Morabito
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Céline Berthon
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Lionel Adès
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Pierre Fenaux
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Odile Beyne-Rauzy
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Norbert Vey
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Thorsten Braun
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Torsten Haferlach
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - François Dreyfus
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Nicholas C.P. Cross
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Claude Preudhomme
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Olivier A. Bernard
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Michaela Fontenay
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - William Vainchenker
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Susanne Schnittger
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Daniel Birnbaum
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Nathalie Droin
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| | - Eric Solary
- Raphaël Itzykson, Margot Morabito, Olivier A. Bernard, William Vainchenker, Nathalie Droin, Eric Solary, Institut Gustave Roussy, Villejuif; Raphaël Itzykson, Margot Morabito, William Vainchenker, Nathalie Droin, Eric Solary, Université Paris-Sud, Le Kremlin-Bicêtre, Orsay; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Assistance Publique–Hôpitaux de Paris, Hôpital Cochin; Olivier Kosmider, François Dreyfus, Michaela Fontenay, Université Paris Descartes; Olivier Kosmider, Michaela Fontenay,
| |
Collapse
|
47
|
Vuotto F, Berthon C, Lemaitre N, Duhamel A, Balkaran S, Le Ray E, Micol JB, Faure K, Alfandari S. Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study. Am J Infect Control 2013; 41:527-30. [PMID: 23219670 DOI: 10.1016/j.ajic.2012.07.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Revised: 07/15/2012] [Accepted: 07/16/2012] [Indexed: 11/16/2022]
Abstract
BACKGROUND We observed an increased rate of Pseudomonas aeruginosa bacteremia in our hematology unit in 2004-2007 without an identified environmental source. METHODS We conducted a matched case-control study to investigate factors associated with P aeruginosa bacteremia in patients with hematologic malignancies. RESULTS Forty-two episodes of P aeruginosa bacteremia were identified. At presentation, 26 patients (62%) had pneumonia and 9 patients (21%) were in shock. Twenty-five patients (60%) were aplastic. The clinical cure rate was 40%. Comparing the 42 cases with 84 matched controls identified the following independent risk factors for P aeruginosa bacteremia: hospitalization in the previous 3 months (odds ratio [OR], 12.84; 95% confidence interval [CI], 2.98-55.18), antibiotic therapy in the previous 3 months (OR, 5.34; 95% CI, 2.14-13.30), receipt of ceftriaxone in the previous 3 months (OR, 2.38; 95% CI, 1.08-5.27), receipt of aminoglycosides in the previous 3 months (OR, 6.65; 95% CI, 1.15-38.25) and receipt of fluoroquinolones in the previous 3 months (OR, 3.22; 95% CI, 1.48-7.00). CONCLUSIONS Local antibiotic therapy algorithms were modified to decrease prescriptions of ceftriaxone and combination therapy with aminoglycosides and fluoroquinolones in an effort to decrease the risk of P aeruginosa bacteremia.
Collapse
Affiliation(s)
- Fanny Vuotto
- Department of Infectious Diseases, Claude Huriez Hospital, University of Lille, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Pascal L, Beyne-Rauzy O, Brechignac S, Marechaux S, Vassilieff D, Ernst O, Berthon C, Gyan E, Gourin MP, Dreyfus F, Fenaux P, Rose C. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol 2013; 162:413-5. [DOI: 10.1111/bjh.12368] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Laurent Pascal
- Service d'Hématologie et de cardiologie Hôpital Saint Vincent de Paul; Université Catholique de Lille; Lille; France
| | | | | | - Sylvestre Marechaux
- Service d'Hématologie et de cardiologie Hôpital Saint Vincent de Paul; Université Catholique de Lille; Lille; France
| | | | - Olivier Ernst
- Radiologie; Hôpital Huriez; CHU de Lille; Lille; France
| | | | | | | | | | | | | |
Collapse
|
49
|
Prebet T, Wanquet A, Sebert M, Roux C, Berthon C, Micol J, Recher C, Dreyfus F, Fenaux P, Vey N. P-273 Azacitidine treatment for patients with myelodysplastic syndrom and acute myeloid leukemia harboring chromosome 3q abnormalities. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70320-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
50
|
Berthon C, Fontenay M, Corm S, Briche I, Allorge D, Hennart B, Lhermitte M, Quesnel B. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res 2013; 37:573-9. [DOI: 10.1016/j.leukres.2013.02.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Revised: 12/21/2012] [Accepted: 02/02/2013] [Indexed: 11/16/2022]
|